Skip to main content

Pharmacokinetics of ASKP1240

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
2
ASKP1240Phase 12 trials
ASP1240Phase 11 trial
Active Trials
NCT01780844Completed149Est. Jan 2017
NCT01582399Completed24Est. Sep 2012
NCT01565681Completed109Est. Dec 2009
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
ASKP1240PHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasASKP1240
AstellasASKP1240
AstellasASP1240

Clinical Trials (3)

Total enrollment: 282 patients across 3 trials

NCT01780844AstellasASKP1240

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Start: Mar 2013Est. completion: Jan 2017149 patients
Phase 2Completed
NCT01582399AstellasASKP1240

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

Start: Feb 2012Est. completion: Sep 201224 patients
Phase 1Completed
NCT01565681AstellasASP1240

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

Start: Jan 2009Est. completion: Dec 2009109 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.